Bi-456,906
Bi-456,906 has been studied in 1 paper since 2021: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Jul 6, 2021: “Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity”.
1 paper studies itUpdated
- 20 trials, 6 about aging, 2 with no results posted
- 20 of 20 trials sponsored by its developers
Has Bi-456,906 been tested in people?
6 about aging, of 23No study of it in people has been published yet.
About aging
Phase 3Completed
Phase 1Active, not recruiting
Phase 3Not yet recruiting
Phase 3Completed
Phase 3Completed
Phase 3Not yet recruiting
Who is developing Bi-456,906?
1 company: Boehringer Ingelheim.
- Companies
- Boehringer IngelheimPhase 3obesity, type 2 diabetes
Trial sponsors
Company8 trialsPhase 310,065 people
Latest
Expert Opinion on Emerging Drugs
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
ReviewGLP-1 receptor agonists